M E Safar

Université René Descartes - Paris 5, Lutetia Parisorum, Île-de-France, France

Are you M E Safar?

Claim your profile

Publications (830)3711.27 Total impact


  • No preview · Article · Feb 2016 · The Lancet
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors aimed to investigate the superiority of angiotensin system blockade (angiotensin-converting enzyme [ACE] inhibitor/angiotensin receptor blocker [ARB]) plus a calcium channel blocker (CCB) (A+C) over other combination therapies in antihypertensive treatment. A meta-analysis in 20,451 hypertensive patients from eight randomized controlled trials was conducted to compare the A+C treatment with other combination therapies in terms of blood pressure (BP) reduction, clinical outcomes, and adverse events. The results showed that BP reduction did not differ significantly among the A+C therapy and other combination therapies in systolic and diastolic BP (P=.87 and P=.56, respectively). However, A+C therapy, compared with other combination therapies, achieved a significantly lower incidence of cardiovascular composite endpoints, including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke (risk ratio [RR], 0.80; 95% confidence interval [CI], 0.70–0.91; P<.001), but similar all-cause mortality (RR, 0.90; 95% CI, 0.77–1.04; P=.15) and stroke rates (RR, 0.90; 95% CI, 0.77–1.04; P=.09). Moreover, A+C therapy yielded a 4.21 mL/min/1.73 m2 lower estimated glomerular filtration rate reduction than other combinations (P<.001). Finally, A+C therapy showed a similar incidence of adverse events as other combination therapies (P=.34) but presented a significantly lower incidence of serious adverse events (RR, 0.85; 95% CI, 0.73–0.98; P=.03). In conclusion, A+C therapy is superior to other combinations of antihypertensive treatment as it shows a lower incidence of cardiovascular events and adverse events, while it has similar effects in lowering BP and preserving renal function.
    No preview · Article · Jan 2016 · Journal of Clinical Hypertension
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Enhanced aortic stiffness and blood pressure variability (BPV) are independent risk factors for cardiovascular disease and all-cause mortality in man. They are also correlated with increased blood pressure (BP) and/or arterial remodeling. However, the interplay between BP and BPV on the stiffening process is still unclear. Our objectives were to determine the temporal evolution of both BPV and pulse wave velocity (PWV), a surrogate measure of arterial stiffness, using an animal model of remodeling-dependent aortic stiffening. Method: We thus, developed a new telemetric technique allowing continuous measurement of PWV in conscious, unrestrained rats. Studies were performed in spontaneously hypertensive rats (SHR) treated for 2 weeks with N-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor (SHR-LN). BPV was evaluated conventionally or with a new device composed of two pressure transducers in two different sets of rats. This allowed a continuous monitoring of telemetered PWV, systolic (SPV), diastolic (DPV), and pulse pressure variability (PPV). Aortic structure was then characterized by immunohistochemical analysis. Results: SPV, DPV, and PPV were increased in SHR-LN, when calculated by 24-h SD or using average real variability a parameter used to assess short-term variability in man. We observed rapid and simultaneous increases in BP, SPV, and PWV. Interestingly, PPV was the most increased parameter resulting mainly from different time course of SPV and DPV. Structural alterations of the aortic wall were observed, with a eutrophic inward remodeling and accumulation of fibronectin and its two main receptors ([alpha]5 and [alpha]v integrins). Conclusion: This offers unequivocal evidence of a significant relationship between PWV, BPV, and arterial structure. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 Copyright
    No preview · Article · Jan 2016 · Journal of Hypertension
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to develop an animal model of long-term blood pressure variability (BPV) and to investigate its consequences on aortic damage. We hypothesized that day-to-day BPV produced by discontinuous treatment of spontaneously hypertensive rats (SHR) by valsartan may increase arterial stiffness. For that purpose, rats were discontinuously treated, 2 days a week, or continuously treated by valsartan (30 mg/kg/d in chow) or placebo. Telemetered BP was recorded during 2 min every 15 min, 3 days a week during 8 weeks to cover the full BP variations in response to the treatment schedule. Pulse wave velocity (PWV) and aortic structure evaluated by immunohistochemistry were investigated in a second set of rats treated under the same conditions. Continuous treatment with valsartan reduced systolic BP (SBP) and reversed the aortic structural alterations observed in placebo treated SHR (decrease of medial cross-sectional area). Discontinuous treatment with valsartan decreased SBP to a similar extent but increased the day-to-day BPV, short term BPV, diastolic blood pressure (DBP), and PWV as compared with continuous treatment. Despite no modifications in the elastin/collagen ratio and aortic thickness, an increase in PWV was observed following discontinuous treatment and was associated with a specific accumulation of fibronectin and its αv-integrin receptor compared with both groups of rats. Taken together the present results indicate that a discontinuous treatment with valsartan is able to induce a significant increase in day-to-day BPV coupled to an aortic phenotype close to that observed in hypertension. This experimental model should pave the way for future experimental and clinical studies aimed at assessing how long-term BPV increases aortic stiffness.
    Full-text · Article · Dec 2015 · Frontiers in Physiology
  • Harold Smulyan · Saktipada Mookherjee · Michel E. Safar
    [Show abstract] [Hide abstract]
    ABSTRACT: Adult hypertension can be divided into two relatively distinct forms-systolic/diastolic hypertension in midlife and systolic hypertension of the aged. The two types differ in prevalence, pathophysiology, and therapy. The prevalence of systolic hypertension in the elderly is twice that of midlife hypertension. The systolic pressure is elevated in both forms, but the high diastolic pressure in midlife is due to a raised total peripheral resistance, whereas the normal or low diastolic pressure in the elderly is due to aortic stiffening. Aortic stiffness, as measured by the carotid/femoral pulse wave velocity, has been found to be a cardiovascular risk marker independent of traditional risk factors for atherosclerosis. Instead, it is related to microcirculatory disease of the brain and kidney and to disorders of inflammation. Loss of aortic distensibility is an inevitable consequence of aging, but a review of its causes suggests that it may be amenable to future pharmacologic therapy.
    No preview · Article · Nov 2015 · Journal of the American Society of Hypertension (JASH)
  • Gérard M London · Michel E Safar · Bruno Pannier
    [Show abstract] [Hide abstract]
    ABSTRACT: Aging incurs aortic stiffening and dilation, but these changes are less pronounced in peripheral arteries, resulting in stiffness and geometry gradients influencing progression of the forward and reflected pressure waves. Because premature arterial aging is observed in ESRD, we determined the respective roles of stiffness and aortic geometry gradients in 73 controls and 156 patients on hemodialysis. We measured aortic pulse wave velocity (PWV) and brachial PWV to evaluate the stiffness gradient [(brachial PWV/aortic PWV)(0.5)] and ascending aortic and aortic bifurcation diameters to assess aortic taper (ascending aortic diameter/aortic bifurcation diameter). The global reflection coefficient was estimated from characteristic impedance and vascular resistance. Cox proportional hazard models were used to determine mortality risk. The age-associated increase in aortic PWV was higher in patients (P<0.001). In controls, aortic ascending and bifurcation diameters increased with age, with an unchanged aortic taper. In patients on hemodialysis, age did not associate with increased ascending aortic diameter but did associate with increased aortic bifurcation diameter and decreased aortic taper, both of which also associated with abdominal aortic calcifications and smaller global reflection coefficient (P<0.001). In patients, multivariate models revealed all-cause and cardiovascular mortality associated with age, aortic PWV, and aortic bifurcation diameter with high specificity and sensitivity. Using stiffness gradient, aortic taper, or global reflection coefficient in the model produced similar results. Thus, whereas aortic stiffness is a known independent predictor of mortality, these results indicate the importance of also evaluating the aortic geometry in patients on hemodialysis.
    No preview · Article · Oct 2015 · Journal of the American Society of Nephrology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: No previous population study assessed the diurnal profile of central arterial properties. Methods: In 167 participants (mean age, 56.1 years; 63.5% women), randomly recruited in Montevideo, Uruguay, we used the oscillometric Mobil-O-Graph 24-h PWA monitor to measure peripheral and central systolic (SBP), diastolic (DBP), and pulse (PP) pressures and central hemodynamics standardized to a heart rate of 75 bpm, including aortic pulse wave velocity, systolic augmentation (first/second peak × 100), and pressure amplification (peripheral PP/central PP). Results: Over 24 hours, day and night, peripheral minus central differences in SBP/DBP and in PP averaged 12.2/-1.1, 14.0/-0.7, and 9.7/0.2mm Hg and 12.6, 14.7, and 9.5mm Hg, respectively (P < 0.001 except for nighttime DBP (P = 0.38)). The central-to-peripheral ratios of SBP, DBP, and PP were 0.89, 1.00, and 0.70 unadjusted, but after accounting for anthropometric characteristics decreased to 0.74, 0.97, and 0.63, respectively, with strong influence of height for SBP and DBP and of sex for PP. From day (10-20h) to nighttime (0-6h), peripheral (-10.4/-10.5 mm Hg) and central (-6.0/-11.3mm Hg) SBP/DBP, pulse wave velocity (-0.7 m/s) and pressure amplification (-0.05) decreased (P < 0.001), whereas central PP (+5.3mm Hg) and systolic augmentation (+2.3%) increased (P < 0.001). Conclusions: The diurnal rhythm of central pressure runs in parallel with that of peripheral pressure, but the nocturnal fall in SBP is smaller centrally than peripherally. pulse wave velocity, systolic augmentation, and pressure amplification loop through the day with high pulse wave velocity and pressure amplification but low systolic augmentation in the evening and opposite trends in the morning.
    No preview · Article · Oct 2015 · American Journal of Hypertension
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In a population of 56,242 individuals living in France, we showed that individuals born in France have significantly different levels of blood pressure (BP) and cardiovascular (CV) risk factors than African and Asian populations born in their own country but living long-term in France (average duration of stay, 5-10 years). The objective of our study was to investigate the impact of country of birth on BP and CV risk factors in a subpopulation of 9245 patients selected solely on the diagnosis of hypertension, either alone or with simultaneous type 2 diabetes. In the subgroup of individuals with hypertension alone, brachial systolic, diastolic, mean and pulse pressure (PP), heart rate (HR), augmentation index and PP amplification were significantly higher in African-born than French- and Asian-born populations. In the subgroup of individuals with both hypertension and diabetes, only augmentation index, PP amplification and brachial and central PP, but not brachial systolic, diastolic, mean BP, and HR, were elevated when the African-born subgroup was compared to the French- and Asian-born populations. Increased body mass index (BMI), waist-hip ratio (WHR), and deprivation scores, but not increased plasma lipids or glycemia, were consistently associated with the African-born population. The combination of diabetes and hypertension in African populations was associated with increased aortic stiffness and PP, together with greater body weight and WHR. In individuals with increased PP and hence systolic hypertension, increased PP requires systolic BP to be reduced whereas notable reductions in diastolic BP may have deleterious consequences.
    Preview · Article · Sep 2015 · Frontiers in Physiology

  • No preview · Article · Sep 2015 · La Presse Médicale
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension (HTN) in chronic kidney disease (CKD) is influenced by blood pressure (BP) and the progression of CKD, including hemodialysis and renal transplantation. To date, the efficacy of antihypertensive drug strategies has chiefly been assessed by measuring steady-state systolic, diastolic and mean arterial pressures (MAP). However, recently elucidated features of the BP curve have highlighted other important goals, that is, the specific roles of pulse pressure (PP), arterial stiffness, pulse wave velocity (PWV) and wave reflections as potentially deleterious factors affecting the progression of HTN and CKD. Pharmacological strategies to date have included progressive withdrawal of alpha-blocking agents; efficacy of beta-blockers for coronary prevention; use of angiotensin blockade in HTN with glomerular injury, using angiotensin-converting enzyme inhibition or receptor blockade, as mono but never double-blockade, to avoid major complications; development of combination therapies with diuretics and/or calcium channel blockers. Nowadays, most clinical trials show that SBP, DBP and MAP-lowering is an effective strategy, although results no longer show preference for any specific drug class.Studies of arterial stiffness in CKD have become crucial. In older individuals, PWV is considerably elevated. The 'stiffness gradient' disappears or is inverted (normally, aortic PWV is lower than brachial PWV). Despite BP-lowering, PP is insufficiently dampened, thus promoting microcirculatory damage, progression of arterial calcifications and disturbed wave reflections, which all increase the risk of mortality. In the absence of effective hemodialysis or graft, increased arterial stiffness is therefore a major cardiovascular risk factor in CKD.
    No preview · Article · Jul 2015 · Journal of Hypertension
  • Harold Smulyan · Ari Lieber · Michel E Safar
    [Show abstract] [Hide abstract]
    ABSTRACT: In patients with both hypertension and type II diabetes, the systolic blood pressure (SBP) increases linearly with age, while that of diastolic blood pressure (DBP) declines curvilinearly as early as age 45, all suggesting the development of increased arterial stiffness. Increased stiffness is an important, independent, and significant risk predictor in subjects with hypertension and diabetes. In patients with both diseases, stiffness assessed at the same mean arterial pressure (MAP) was significantly higher in diabetic patients. Arterial stiffness is related to age, heart rate (HR), and MAP, but in diabetic patients, it also related to diabetes duration and insulin treatment (IT). In the metabolic syndrome (MetSyn), diabetes also acts on the small arteries through capillary rarefaction to reduce the effective length of the arterial tree, increases the reflected pulse wave and thus the pulse pressure (PP). These studies indicate that diabetes and hypertension additively contribute to increased pulsatility and suggest that any means to reduce stiffness would be beneficial in these conditions. © American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
    No preview · Article · Jul 2015 · American Journal of Hypertension
  • C Chi · C Tai · J Wang · A Protogerou · J Blacher · M E Safar · Y Zhang · Y Xu
    [Show abstract] [Hide abstract]
    ABSTRACT: Current clinical evidence and latest guidelines recommended the combination antihypertensive therapy with angiotensin-converting enzyme (ACE) inhibitor / angiotensin receptor blocker (ARB) and calcium channel blocker (CCB) in patients with grade 2 to 3 hypertension. However, data are scarce in the comparison between the ACE inhibitor / ARB + CCB (A+C) therapy and other combinations. We therefore conducted a meta-analysis to see if ACE inhibitor/ARB combined with CCB is superior to other combinations.(Figure is included in full-text article.) DESIGN AND METHOD:: A meta-analysis was conducted in 20,669 hypertensives from 9 randomized controlled trials and we compared the A+C therapy with other combinations, in terms of blood pressure (BP) reduction, clinical outcomes and adverse effects. BP reduction did not differ significantly between the A+C therapy and other combination therapies, neither in systolic nor in diastolic BP, with P = 0.43 and P = 0.41, respectively. However, A+C strategy, compared with other combination therapies, achieved a significantly lower incidence of cardiovascular composite endpoints, including cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke (Risk ratio [RR] and 95% confidential interval [CI]: 0.80 [0.70, 0.91], P < 0.001, see as Figure), but similar all-cause mortality (0.90 [0.77, 1.04], P = 0.15) and stroke rate (0.90 [0.77, 1.04], P = 0.09). Moreover, A+C combination therapy exhibited a 3.10 ml/min/1.73m2 greater estimated glomerular filtration rate than other combinations (P = 0.01). Lastly, A+C therapy showed a similar incidence of adverse effects as other combinations (P = 0.34), but had a significantly lower incidence of severe adverse effects (0.85 [0.73, 0.98], P = 0.03). In summary, clinical evidences favor A+C therapy, which is superior to other combinations, in current anti-hypertensive strategy, with greater clinical benefit in cardiovascular outcome and reservation of renal function.
    No preview · Article · Jun 2015 · Journal of Hypertension
  • Athanase Benetos · Sylvie Gautier · Michel E. Safar
    [Show abstract] [Hide abstract]
    ABSTRACT: The 2013 ESC-ESH Guidelines for the management of arterial hypertension stated that in elderly (>80 years) individuals, lowering SBP to < 150mmHg is strongly evidence-based. These guidelines are mainly based on the results of the Hypertension in the Very Elderly (HYVET) study which showed the beneficial effect of decreasing SBP with antihypertensive treatment in patients older than 80 years. This trial was conducted in a highly selected population of robust elderly patients with very low comorbidities. Thus, despite the interest of these results, we believe that the question of the benefits of antihypertensive treatment in the very old is not unequivocally settled and may depend on the magnitude of co-morbidities, frailty and functional decline. The PARTAGE (Predictive values of blood pressure and arterial stiffness in institutionalized very aged population) multicenter study performed in very old, frail subjects living in nursing homes reported a 30% increase in all-cause mortality in patients ranked in the lowest tertile of SBP (<130mmHg) compared to the two upper tertiles. These results remained identical after adjusting for several confounders such as age, gender, history of previous CV disease, index of co-morbidity, cognitive function and autonomy status. These paradoxical results can be explained by the fact that in these very old frail subjects, a low SBP may not simply be a sign of so-called good arterial health, but often of malnutrition and of co-morbidities such as heart failure, neurological disorders etc., as well as other concomitant conditions associated with poor prognosis. Irrespective of the underlying explanation, the present results indicate that the BP levels in very old “frail” individuals are evidently not reliable. These findings raise the question as to relevance of BP levels as an indicator of the cardiovascular risk in these subjects. This is of major interest since iatrogenic-induced problems are also a major issue in geriatric subjects. In fact, at the present time, no study has provided evidence that higher morbidity-mortality rates in those with very low BP is due to low BP in itself or is just a sign of general bad health. Interventional clinical trials will provide critical information to guide physicians in order to fixe specific goals for treating hypertension and decreasing the risk of cardiovascular complications in these very old and frail individuals.
    No preview · Article · Mar 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Arterial stiffening, especially of the large elastic arteries, is a fundamental vascular aging trait, which is, however, accelerated in the presence of genetic and environmental factors. It is an early marker of subclinical arterial disease but also a well-established biomarker of clinical cardiovascular disease events and cardiovascular disease mortality. Preventive strategies calcium channel blockade and allopurinol, a careful individualized de-stiffening strategy on the basis of sodium balance, in combination with the renin-angiotensin system blockade, appears to be the currently available optimal strategy.
    No preview · Article · Mar 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: It was reported that, in addition to blood pressure (BP) level, BP variability could also provide prognostic value of target organ damage, cardiovascular and all-cause mortality. Therefore, evaluation of patients' BP variability could potentially offer guiding information on their clinical therapy. BP variability could be assessed by calculating standard deviation, coefficient of variation and other parameters of BP readings from 24-h ambulatory BP monitor, known as short-term BP variability. More recently, an emerging BP variability can be derived from regular home and office BP recordings for 1 week or several months, known as long-term BP variability. Although the cause and meaning of fluctuated BP was not well elucidated, several factors, including age, mean BP, heart rate variability and arterial stiffness, may influence patients' BP variability. Most clinical investigations indicated a significant prognostic value of either short- or long-term BP variability, with regards to target organ damage, cardiovascular events and mortality, but controversy exists in this field, especially its incremental prognostic value in addition to BP level. Till now, there is no solid evidence indicating any effective agent in terms of BP variability reduction, but some clinical studies favor CCB in reducing both short- and long-term BP variability. Further studies are warranted to investigate the standardized evaluation of patients' BP variation, its cause and added prognostic significance, as well as effective treatment.
    No preview · Article · Mar 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increases in arterial stiffness and pulse pressure are typical features of the arterial stiffness during aging and are associated with increased risk of cardiovascular complications. Cellular and molecular determinants of arterial stiffness have not been completely elucidated. Clinically, the carotid-femoral pulse wave velocity (PWV) is the gold standard parameter of arterial stiffness. A recent genome-wide scan of the Framingham Heart Study population has shown that arterial stiffness and mean and pulsatile components of blood pressure are heritable and map to separate the genetic loci in humans, suggesting that distinct genes may modulate these two phenotypes. This chapter details the recent knowledge on the influence of genetic determinants and telomere length on the development of age-related phenotypes. Recent genetic studies have revealed specific genes contributing to arterial stiffening. Available data on genome-wide association (GWA) have been initiated on PWV and have identified common genetic variation in specific loci or single-nucleotide polymorphisms (SNP) significantly associated with PWV. Telomere length at birth is strongly determined genetically and is the main determinant of leukocytes' telomere length (LTL) later in life. Short LTL is associated with increased risk of stiffness and atherosclerosis of the carotid artery, atherosclerotic heart disease, and diminished survival in the elderly.
    No preview · Article · Mar 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal transplantation is the best renal replacement modality for patients with end-stage renal disease in terms of patient survival and quality of life. Despite substantial improvement in recipient outcome, stiffness of the large arterial system and cardiovascular (CV) mortality remain high compared to age- and sex-matched subjects in the general population. In addition to traditional CV risk factors, transplantation-specific parameters emerge and are related to immune interactions, drug specifications, and donor characteristics. Some of these parameters appear to be modulators of risk factors and graft and recipient outcome. Acute rejection, for example, appears as a major and independent determinant of high arterial stiffness in recipients of kidney grafts. Furthermore, past history of CV events, low graft filtration function, and donor age determine long-term patient and graft outcome. Living kidney donors, on the other hand, are normally protected especially that they are carefully selected prior to transplantation. Despite a similar long-term outcome compared to the general population, donors may be at higher risk for stiffening of the large arterial system, especially if they cluster with time, CV comorbidities.
    No preview · Article · Mar 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent clinical investigations, visit-to-visit systolic blood pressure (SBP) variability was proven as a predictor of cardiovascular events and all-cause mortality. However, inconsistent results exist in this association. A meta-analysis of 13 prospective studies was conducted to evaluate the prognostic value of visit-to-visit SBP variability by different parameters in 77,299 patients with a mean follow-up of 6.3 years. The pooled age- and mean SBP-adjusted hazard ratios (HRs) for all-cause mortality were 1.03 (95% confidence interval [CI], 1.02-1.04; P<.001) per 1-mm Hg increase in SBP standard deviation (SD) and 1.04 (1.02-1.06, P<.001) per 1% in SBP coefficient of variation, and the corresponding values of cardiovascular mortality were 1.10 (1.02-1.17, P<.001) and 1.01 (0.99-1.03, P=.32), respectively. Moreover, a 1-mm Hg increase in SD was significantly associated with stroke, with an HR of 1.02 (1.01-1.03, P<.001). Visit-to-visit SBP variability, independent of age and mean SBP, is a predictor of cardiovascular and all-cause mortality and stroke. ©2015 Wiley Periodicals, Inc.
    Preview · Article · Feb 2015 · Journal of Clinical Hypertension
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/Aims: Renal function decreases over time as a result of reduction in the number of functioning nephrons with age. In recipients and donors of kidney grafts, renal function decline may be linked differently to various parameters, namely arterial stiffness. Methods: We conducted a prospective cohort study including 101 recipients of kidney grafts and their donors aiming at determining the factors correlating with renal function decline over time. Aortic stiffness was evaluated by the non-invasive measurement of aortic pulse wave velocity. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease equation and the annualized change was determined. Results: Decline in renal function was estimated at 1-year post-transplantation and annually thereafter (median follow-up 8 years, range 3.6-18.3), as the mean of the annualized decrease in the glomerular filtration rate. In recipients, filtration rate decreased by 4.8 ± 19.7 mL/min/1.73m2 the first post-transplant year, and at a yearly rate of 2.2 ± 3.8 mL/min/1.73m2 thereafter. The first year decline was related to smoking and acute rejection. Later decline was significantly associated with donor age and aortic stiffness. In living donors, renal function decline after the first year corresponded to 0.7 mL/min/1.73m2, was significantly lower than that of recipients (p<0.001), and was determined by donor age at nephrectomy. Conclusion: Recipients of kidney grafts show a glomerular filtration rate decline over time that is significantly associated with donor age and aortic stiffness after the first post-transplant year, while donors demonstrate a lower decline that is mostly determined by age at nephrectomy.
    Full-text · Article · Dec 2014 · American Journal of Nephrology
  • Michel E Safar · Gérard E Plante · Albert Mimran
    [Show abstract] [Hide abstract]
    ABSTRACT: Classical studies indicate that the contribution of kidneys to hypertension is almost exclusively related to the association between mean arterial pressure (MAP) and vascular resistance. Recent reports including estimates of glomerular filtration rate (GFR) have shown that pulse pressure (PP) and pulse wave velocity, 2 major indices of arterial stiffness, now emerge as significant predictors of cardiovascular risk and age-associated decline in GFR. Such findings are mainly observed in patients with hypertension and renal failure and in atherosclerotic subjects undergoing coronary angiography. In such patients, amplification of PP between ascending and terminal aorta at the renal site is constantly increased over 10mm Hg (P < 0.001), whereas MAP level remains continuously unmodified. This PP amplification is significantly associated with presence of proteinuria. Furthermore, increases in plasma creatinine and aortic stiffness are independently and positively correlated (P < 0.001) both in cross-sectional and longitudinal studies. All these relationships associating PP, arterial stiffness, and renal function are mainly observed in patients 60 years of age or older. Furthermore, in renal transplant patients and their donors, subjects have been recruited for evaluations of arterial stiffness and posttransplant decline in GFR. Determinants of GFR decline were evaluated 1 and 9 years after transplantation. The first year GFR decline was related to smoking and acute rejection, whereas the later was significantly and exclusively associated with donor age and aortic stiffness. Thus, in hypertensive humans, the observed association between PP and GFR suggests that the 2 parameters are substantially mediated by arterial stiffness, not exclusively by vascular resistance. © American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
    No preview · Article · Dec 2014 · American Journal of Hypertension

Publication Stats

33k Citations
3,711.27 Total Impact Points

Institutions

  • 2006-2015
    • Université René Descartes - Paris 5
      • Faculté de Médecine
      Lutetia Parisorum, Île-de-France, France
    • University of Miami
      كورال غيبلز، فلوريدا, Florida, United States
    • University of Florida
      Gainesville, Florida, United States
  • 1990-2015
    • Hôtel-Dieu de Paris – Hôpitaux universitaires Paris Centre
      Lutetia Parisorum, Île-de-France, France
  • 2002-2013
    • University of New South Wales
      Kensington, New South Wales, Australia
    • University of Milan
      Milano, Lombardy, Italy
    • Centre Chirurgical Marie Lannelongue
      Plessis-Robinson, Île-de-France, France
  • 2007-2012
    • Assistance Publique – Hôpitaux de Paris
      Lutetia Parisorum, Île-de-France, France
    • Hôpital "Sainte-Périne - Rossini - Chardon-Lagache" – Hôpitaux universitaires Paris Ile-de-France Ouest
      Lutetia Parisorum, Île-de-France, France
    • National and Kapodistrian University of Athens
      • Division of Clinical Therapeutics
      Athínai, Attica, Greece
    • Centre Hospitalier Universitaire de Montpellier
      Montpelhièr, Languedoc-Roussillon, France
    • Charles University in Prague
      • Department of Internal Medicine (2. LF)
      Praha, Praha, Czech Republic
  • 2011
    • St. James's Hospital
      Dublin, Leinster, Ireland
  • 2010
    • Victor Chang Cardiac Research Institute
      Darlinghurst, New South Wales, Australia
  • 1989-2009
    • French Institute of Health and Medical Research
      • Paris-Cardiovascular Research Center PARCC
      Lutetia Parisorum, Île-de-France, France
  • 2003-2008
    • State University of New York Upstate Medical University
      • Department of Medicine
      Syracuse, NY, United States
    • Cea Leti
      Grenoble, Rhône-Alpes, France
  • 2001-2007
    • Maastricht University
      • Department of Pharmacology
      Maestricht, Limburg, Netherlands
    • St. Vincent Hospital
      Green Bay, Wisconsin, United States
    • ICPS - Institut Cardiovasculaire Paris Sud
      Масси, Île-de-France, France
  • 2004-2006
    • University Medical Center – Rizk Hospital
      Beyrouth, Beyrouth, Lebanon
    • University of Naples Federico II
      Napoli, Campania, Italy
    • Université de Sherbrooke
      Шербрук, Quebec, Canada
    • Hotel Dieu Hospital
      Kingston, Ontario, Canada
    • French National Centre for Scientific Research
      Lutetia Parisorum, Île-de-France, France
    • Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest)
      Lutetia Parisorum, Île-de-France, France
  • 1998-2005
    • University of Leuven
      • Division of Hypertension and Cardiovascular
      Louvain, Flanders, Belgium
  • 2000-2002
    • Centre D'Investigations Préventives Et Cliniques
      Lutetia Parisorum, Île-de-France, France
    • Catholic University of Louvain
      Лувен-ла-Нев, Walloon, Belgium
  • 1989-2002
    • Unité Inserm U1077
      Caen, Lower Normandy, France
  • 1989-1996
    • American Hospital of Paris
      Lutetia Parisorum, Île-de-France, France
  • 1991
    • Innovació i Recerca Industrial i Sostenible
      Castelldefels, Catalonia, Spain
  • 1987
    • University of Vienna
      Wien, Vienna, Austria
  • 1979-1982
    • University of Lyon
      Lyons, Rhône-Alpes, France
    • Centre Hospitalier de Meaux
      Мо, Île-de-France, France
  • 1980
    • Clinique Ambroise Paré
      Tolosa de Llenguadoc, Midi-Pyrénées, France
  • 1976-1979
    • Université de Picardie Jules Verne
      Amiens, Picardie, France